Diffusion‐weighted imaging in Huntington's disease

Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder that results from an expanded trinucleotide (CAG) repeat on the huntingtin gene. Neurodegeneration in HD affects most prominently the basal ganglia. Therefore, diffusivity was obtained in the basal ganglia and thalamus of 29 patients with early HD and 27 healthy volunteers by means of the trace of the diffusion tensor (Trace(D)). Putaminal, caudate, pallidal, and thalamic Trace(D) values were increased in patients with HD compared with controls. Increased diffusivity in the putamen and caudate nucleus correlated with global functional impairment, CAG repeat length, as well as bicaudate ratio. Diffusion‐weighted imaging appears to be a promising surrogate marker for disease severity in HD. Sensitivity to change remains to be established longitudinally. © 2006 Movement Disorder Society

[1]  G D Pearlson,et al.  Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. , 1996, Archives of neurology.

[2]  Derek K Jones,et al.  Applications of diffusion‐weighted and diffusion tensor MRI to white matter diseases – a review , 2002, NMR in biomedicine.

[3]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[4]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[5]  Christian Kremser,et al.  Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease , 2004, NeuroImage.

[6]  A. J. Thompson,et al.  Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis , 2003, Journal of Neurology.

[7]  C Kremser,et al.  Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.

[8]  J. D. de Yébenes,et al.  Clinical correlation of striatal 1H MRS changes in Huntington’s disease , 1999, Neurology.

[9]  A. Uluğ,et al.  Diffusion changes in the aging human brain. , 2000, AJNR. American journal of neuroradiology.

[10]  N Makris,et al.  Striatal volume loss in HD as measured by MRI and the influence of CAG repeat , 2001, Neurology.

[11]  Werner Jaschke,et al.  Comparison of diffusion‐weighted imaging and [123I]IBZM‐SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[12]  W. Weiner.  Parkinson’s Disease and Movement Disorders , 2000, Current Clinical Practice.

[13]  H. Heinsen,et al.  Nerve cell loss in the thalamic mediodorsal nucleus in Huntington’s disease , 1999, Acta Neuropathologica.

[14]  M. MacDonald,et al.  CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.

[15]  D. Brock,et al.  A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. , 1993, Molecular and cellular probes.

[16]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[17]  M. Kaste,et al.  Diffusion-weighted MR imaging in normal human brains in various age groups. , 2002, AJNR. American journal of neuroradiology.

[18]  Denis Le Bihan,et al.  Looking into the functional architecture of the brain with diffusion MRI , 2003, Nature Reviews Neuroscience.

[19]  Mario Mascalchi,et al.  Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. , 2004, Radiology.

[20]  O. Riess,et al.  DNA analysis of Huntington’s disease , 1999, Neurology.

[21]  O. Riess,et al.  Avoiding errors in the diagnosis of (CAG)n expansion in the huntingtin gene. , 1997, Journal of medical genetics.

[22]  Guidelines for the molecular genetics predictive test in Huntington's disease , 1994, Neurology.

[23]  A. Cooper,et al.  The selective vulnerability of striatopallidal neurons , 1999, Progress in Neurobiology.

[24]  D. Eidelberg,et al.  [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.

[25]  G Pearlson,et al.  Bicaudate ratio as a measure of caudate volume on MR images. , 1991, AJNR. American journal of neuroradiology.

[26]  O. Suchowersky,et al.  Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. , 1996, Annals of neurology.

[27]  P Boesiger,et al.  Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.

[28]  S. Folstein,et al.  Neuropsychological and neuroradiological correlates in Huntington's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[29]  D. Brooks,et al.  Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory? , 1996, Movement disorders : official journal of the Movement Disorder Society.

[30]  G. Pearlson,et al.  Longitudinal change in basal ganglia volume in patients with Huntington's disease , 1997, Neurology.

[31]  C. Tessa,et al.  Longitudinal evaluation of leukoaraiosis with whole brain ADC histograms , 2002, Neurology.

[32]  M. Hayden,et al.  Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.

[33]  International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. , 1994, Journal of medical genetics.

[34]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[35]  B. Harper.  Huntington Disease , 2005, Journal of the Royal Society of Medicine.

[36]  C Kremser,et al.  Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD , 2002, Neurology.

[37]  C D Marsden,et al.  Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography , 1986, Movement disorders : official journal of the Movement Disorder Society.

[38]  P. Schaefer.  Applications of DWI in clinical neurology , 2001, Journal of the Neurological Sciences.

[39]  O. Suchowersky,et al.  Relationship between trinucliotide repeats and neuropathological changes in Huntington's diease , 1996, Annals of neurology.